XNASACON
Market cap1mUSD
Dec 24, Last price
0.13USD
1D
1.66%
1Q
-27.29%
IPO
-94.95%
Name
Aclarion Inc
Chart & Performance
P/E
—
P/S
17.82
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
75k
+24.75%
Net income
-5m
L-46.10%
CFO
-4m
L-31.37%
Profile
Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in San Mateo, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 75 24.75% | 60 0.25% | 60 23.93% | ||
Cost of revenue | 4,951 | 6,159 | 3,013 | ||
Unusual Expense (Income) | |||||
NOPBT | (4,876) | (6,099) | (2,953) | ||
NOPBT Margin | |||||
Operating Taxes | 1,506 | (1,416) | |||
Tax Rate | |||||
NOPAT | (4,876) | (7,605) | (1,537) | ||
Net income | (4,911) -46.10% | (9,112) 157.79% | (3,535) -26.21% | ||
Dividends | (416) | ||||
Dividend yield | 187.74% | ||||
Proceeds from repurchase of equity | 1,462 | 8,552 | |||
BB yield | -1,312.79% | -3,864.11% | |||
| Debt | |||||
Debt current | 1,126 | 5 | 2,000 | ||
Long-term debt | |||||
Deferred revenue | |||||
Other long-term liabilities | 458 | ||||
Net debt | 105 | (1,468) | 1,547 | ||
| Cash flow | |||||
Cash from operating activities | (3,647) | (5,314) | (2,350) | ||
CAPEX | (209) | (152) | |||
Cash from investing activities | (120) | (208) | (152) | ||
Cash from financing activities | 3,315 | 6,552 | 2,940 | ||
FCF | (4,102) | (12,482) | (2,539) | ||
| Balance | |||||
Cash | 1,021 | 1,473 | 453 | ||
Long term investments | |||||
Excess cash | 1,017 | 1,470 | 450 | ||
Stockholders' equity | (44,282) | (39,907) | (31,886) | ||
Invested Capital | 44,679 | 41,699 | 28,156 | ||
ROIC | |||||
ROCE | 79.18% | ||||
| EV | |||||
Common stock shares outstanding | 557 | 382 | 57 | ||
Price | 0.20 -65.52% | 0.58 | |||
Market cap | 111 -49.68% | 221 | |||
EV | 216 | (1,247) | |||
EBITDA | (4,713) | (5,905) | (2,764) | ||
EV/EBITDA | 0.21 | ||||
Interest | 608 | 1,508 | 476 | ||
Interest/NOPBT | |||||